Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of <scp>GLP</scp> ‐1 Receptor Agonists
GLP-1RA discontinuation should be considered a high-risk clinical transition rather than a treatment endpoint. Structured follow-up and multidisciplinary management are essential to preserve long-term cardiometabolic benefits.
Authors
- Laşin Özbek (ORCID: https://orcid.org/0000-0002-2828-555X)
- E Abu Shah
- Adrian Covic
- Mehmet Kanbay
- Rama AlShiab
- Anas Abdo
Institutions
- Koç University (TR)
- Grigore T. Popa University of Medicine and Pharmacy (RO)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1111/dom.70713
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00